Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relmada Therapeutics, Inc. - Common Stock (NQ:RLMD)

0.3108 +0.0210 (+7.25%)
Streaming Delayed Price Updated: 11:29 AM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relmada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Earnings Scheduled For March 27, 2025
Via Benzinga
Insights Ahead: Relmada Therapeutics's Quarterly Earnings
Via Benzinga
A Look Ahead: Relmada Therapeutics's Earnings Forecast
Via Benzinga
Recap: Relmada Therapeutics Q4 Earnings
Via Benzinga
Earnings Outlook For Relmada Therapeutics
Via Benzinga
Earnings Outlook For Relmada Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals. 
Via Benzinga
Nasdaq Surges 150 Points; ISM Services PMI Falls In November
Via Benzinga
Dow Gains 250 Points; Salesforce Shares Jump After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024
RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
7 Penny Biotech Stocks to Triple Your Investment
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. 
Via InvestorPlace
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024
RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023
RLMD stock results show that Relmada Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 19, 2024
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million. 
Via Benzinga
Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.< 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study
Relmada Therapeutics Inc (NASDAQ: RLMD) announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3... 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick
For investors who choose wisely, profits in healthcare stocks can be spectacular. But the losses can also be dramatic if you choose poorly. 
Via InvestorPlace
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.